Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22557792 | 1.00 | HDAC6 (0.54) | HDAC6HDAC1 | |
| SCHEMBL31535160 | 0.92 | HDAC6 (0.57) | HDAC6HDAC1 | |
| SCHEMBL25349454 | 0.92 | HDAC6 (0.57) | HDAC6HDAC1 | |
| SCHEMBL25429626 | 0.92 | HDAC6 (0.56) | HDAC6 | |
| SCHEMBL31535148 | 0.92 | HDAC6 (0.56) | HDAC6 | |
| SCHEMBL22557843 | 0.91 | HDAC6 (0.53) | HDAC6HDAC1 | |
| SCHEMBL22557457 | 0.89 | HDAC6 (0.60) | HDAC6HDAC1 | |
| SCHEMBL25350979 | 0.89 | HDAC6 (0.55) | HDAC6HDAC1 | |
| SCHEMBL31535124 | 0.89 | HDAC6 (0.55) | HDAC6HDAC1 | |
| SCHEMBL29402117 | 0.89 | HDAC6 (0.60) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157398-B | Oxadiazole-based selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-11 | — | — | CN | claimed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | claimed |
| CN-116157398-B | Oxadiazole-based selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12202823-B2 | 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors | QUIMATRYX, S.L. (ES) | 2025-01-21 | — | — | US | disclosed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | FUNDACIÓN KERTOR (ES) | 2022-07-07 | — | — | US | disclosed |
| EP-3956324-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | QUIMATRYX, S.L. (ES) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213084-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885 |
| US-12202823-B2 | 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.